VIALE, GIULIA
 Distribuzione geografica
Continente #
EU - Europa 670
AS - Asia 384
NA - Nord America 236
SA - Sud America 47
AF - Africa 4
Continente sconosciuto - Info sul continente non disponibili 1
Totale 1.342
Nazione #
RU - Federazione Russa 490
US - Stati Uniti d'America 224
SG - Singapore 164
CN - Cina 124
IT - Italia 85
BR - Brasile 40
HK - Hong Kong 39
VN - Vietnam 28
DE - Germania 25
FR - Francia 21
GB - Regno Unito 14
FI - Finlandia 10
IN - India 10
NL - Olanda 9
CA - Canada 6
AT - Austria 4
JP - Giappone 4
MX - Messico 4
ES - Italia 3
PL - Polonia 3
BD - Bangladesh 2
CO - Colombia 2
CR - Costa Rica 2
EC - Ecuador 2
ID - Indonesia 2
IQ - Iraq 2
KG - Kirghizistan 2
UA - Ucraina 2
UZ - Uzbekistan 2
AE - Emirati Arabi Uniti 1
AR - Argentina 1
EG - Egitto 1
ET - Etiopia 1
IE - Irlanda 1
JO - Giordania 1
LB - Libano 1
LK - Sri Lanka 1
PK - Pakistan 1
PT - Portogallo 1
SE - Svezia 1
SK - Slovacchia (Repubblica Slovacca) 1
SR - Suriname 1
TN - Tunisia 1
VE - Venezuela 1
XK - ???statistics.table.value.countryCode.XK??? 1
ZA - Sudafrica 1
Totale 1.342
Città #
Moscow 115
Singapore 108
Hong Kong 38
Ashburn 35
San Jose 28
Dallas 22
Beijing 21
Milan 21
Lauterbourg 17
Council Bluffs 14
Shanghai 14
Boardman 11
Ho Chi Minh City 11
Nuremberg 11
Orem 10
Hanoi 9
Hefei 9
Los Angeles 9
New York 9
Chennai 6
Chicago 6
Rome 6
Santa Clara 6
Helsinki 5
London 5
São Paulo 5
Denver 4
Mexico City 4
Cesano Boscone 3
Cornaredo 3
Costa de' Nobili 3
Frankfurt am Main 3
Lappeenranta 3
Montreal 3
Naples 3
Phoenix 3
St Louis 3
Tokyo 3
Bari 2
Barnet 2
Bekasi 2
Bishkek 2
Brooklyn 2
Buffalo 2
Cagliari 2
Falkenstein 2
Fucecchio 2
Jequié 2
Livorno 2
Paris 2
Pisa 2
Poplar 2
Porto Alegre 2
San José 2
Verona 2
Warsaw 2
Wolfhagen 2
Addis Ababa 1
Amman 1
Amsterdam 1
Andradas 1
Annapolis 1
Araguaína 1
Atlanta 1
Aurora 1
Bandaragama 1
Bauru 1
Biên Hòa 1
Bologna 1
Bolzano 1
Boydton 1
Brasília 1
Bratislava 1
Buena Fe 1
Byblos 1
Bắc Ninh 1
Cabo Frio 1
Cachoeirinha 1
Caicó 1
Cairo 1
Calgary 1
Cali 1
Cape Town 1
Cartagena 1
Catania 1
Caxias do Sul 1
Charleston 1
City of London 1
Coimbatore 1
Coruripe 1
Curitiba 1
Dachne 1
Dnipro 1
Dongguan 1
Dublin 1
Garanhuns 1
Greely 1
Guangzhou 1
Guarapari 1
Haiphong 1
Totale 670
Nome #
Management of Trastuzumab Deruxtecan-related nausea and vomiting in real-world practice 148
Breast cancers with high proliferation and low ER-related signalling have poor prognosis and unique molecular features with implications for therapy 102
Pan-cancer analysis of antibody-drug conjugate targets and putative predictors of treatment response 100
Completion Rate and Positive Results Reporting among Immunotherapy Trials in Breast Cancer, 2004-2023 94
Tissue- and liquid biopsy-based biomarkers for immunotherapy in breast cancer 92
Oncotype DX results increase concordance in adjuvant chemotherapy recommendations for early-stage breast cancer 73
Neoadjuvant immunotherapy in triple-negative breast cancer: lesson learnt, remaining questions 62
The TRAR gene classifier to predict response to neoadjuvant therapy in HER2-positive and ER-positive breast cancer patients: an explorative analysis from the NeoSphere trial 60
Personalized Risk–Benefit Ratio Adaptation of Breast Cancer Care at the Epicenter of COVID-19 Outbreak 59
Determinants of response and molecular dynamics in HER2+ER+ breast cancers from the NA-PHER2 trial receiving HER2-targeted and endocrine therapies 46
HER2-Low breast cancer: Pathological and clinical landscape 45
Immunotherapy in Breast Cancer Patients: A Focus on the Use of the Currently Available Biomarkers in Oncology 39
From intrinsic to adaptive clusters in breast cancer 36
Timing of Recurrence after Neoadjuvant Chemo-Immunotherapy in Patients with Early-Stage Triple-Negative Breast Cancer 33
Overcoming Resistance to CDK4/6 inhibitors in Hormone Receptor positive, HER2 negative breast cancer: Innovative Combinations and Emerging Strategies 33
Body mass index, adiposity and tumour infiltrating lymphocytes as prognostic biomarkers in patients treated with immunotherapy: A multi-parametric analysis 33
Recent advances in triple negative breast cancer: The immunotherapy era 33
Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies 32
Pretreatment Blood Parameters Predict Efficacy from Immunotherapy Agents in Early Phase Clinical Trials 32
Opportunities and challenges of implementing Pharmacogenomics in cancer drug development 32
Harmonizing gene signatures to predict benefit from adjuvant chemotherapy in early breast cancer 31
Tumor-specific major histocompatibility-II expression predicts pathological complete response to atezolizumab combined to chemotherapy in triple-negative breast cancer 29
Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer 29
Profile of buparlisib and its potential in the treatment of breast cancer: Evidence to date 29
Safety, Tolerability, and Management of Toxic Effects of Phosphatidylinositol 3-Kinase Inhibitor Treatment in Patients with Cancer: A Review 28
The evolving landscape of ‘next-generation’ immune checkpoint inhibitors: A review 26
Development and validation of a gene expression-based Breast Cancer Purity Score 15
Trastuzumab Biosimilars Setting the Pace for the Provision of a Cost Effective Oncological Care: Regulatory and Clinical Issues 15
The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer 14
De-escalation strategies for axillary management at primary surgery in early breast cancer: insights and implications for medical oncology practice 2
Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial 1
Totale 1.403
Categoria #
all - tutte 4.060
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.060


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/20232 2 0 0 0 0 0 0 0 0 0 0 0
2023/202419 0 0 0 0 0 0 0 0 0 0 8 11
2024/2025207 29 11 3 14 19 29 28 30 14 8 8 14
2025/20261.174 37 44 21 70 87 118 104 146 474 73 0 0
Totale 1.403